Aptinyx (APTX) Reports Q3 Loss of $0.31/sh
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Aptinyx Reports Third Quarter 2021 Financial Results and Recent Highlights
November 9, 2021 4:05 PM ESTCompleted enrollment in Phase 2b study of NYX-2925 in patients with painful diabetic peripheral neuropathy; results expected in early to mid 2Q 2022
Phase 2b fibromyalgia study and exploratory Phase 2 cognitive impairment study remain on track for readouts in 2022
PTSD Phase 2b program is set to initiate in 4Q 2021
Strong balance sheet supports Phase 2 data readouts from all four clinical development programs
Management to host conference call today at 5:00 p.m. ET
EVANSTON, Ill.--(BUSINESS WIRE)-- Aptinyx Inc. (Nasdaq:... More
